Farther Finance Advisors’s NovoCure NVCR Stock Holding History

Farther Finance Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.1K	Buy	1,114 +370	+50%	+$4.62K	﹤0.01%	3981
2025 Q4	$9.62K	Sell	744 -306	-29%	-$3.93K	﹤0.01%	3947
2025 Q3	$13.6K	Buy	1,050 +556	+113%	+$7.43K	﹤0.01%	3277
2025 Q2	$8.79K	Sell	494 -203	-29%	-$3.54K	﹤0.01%	3138
2025 Q1	$12.2K	Buy	697 +443	+174%	+$10.1K	﹤0.01%	2644
2024 Q4	$7.57K	Buy	254 +108	+74%	+$2.29K	﹤0.01%	2487
2024 Q3	$2.28K	Buy	146 +17	+13%	+$308	﹤0.01%	2954
2024 Q2	$2.24K	Buy	129 +37	+40%	+$651	﹤0.01%	2751
2024 Q1	$1.43K	Sell	92 -264	-74%	-$3.88K	﹤0.01%	2637
2023 Q4	$5.32K	Buy	356 +339	+1,994%	+$4.54K	﹤0.01%	1942
2023 Q3	$275	Buy	17 +13	+325%	+$375	﹤0.01%	2408
2023 Q2	$166	Buy	+4	New	+$248	﹤0.01%	2385

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Farther Finance Advisors's NVCR Position: Q1 2026 in Review

Farther Finance Advisors increased its NovoCure (NVCR) stake by 50% in Q1 2026, buying an estimated $4.62K and bringing the position to 1,114 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

Farther Finance Advisors first reported a position in NVCR in Q2 2023 and has held it in 12 quarters since. The position peaked at $13.6K in Q3 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Farther Finance Advisors held 1,114 shares of NovoCure worth $12.1K as of Q1 2026.
Farther Finance Advisors bought 370 NovoCure shares in Q1 2026, an estimated $4.62K.
NovoCure made up ﹤0.01% of Farther Finance Advisors's portfolio in Q1 2026, its #3981 holding.
Farther Finance Advisors first reported a position in NovoCure in Q2 2023 and has held it in 12 quarters since.
Farther Finance Advisors's NovoCure position peaked at $13.6K in Q3 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.